TY - JOUR
T1 - Optimization of a technology-supported physical activity intervention for breast cancer survivors
T2 - Fit2Thrive study protocol
AU - Phillips, Siobhan M.
AU - Collins, Linda M.
AU - Penedo, Frank J.
AU - Courneya, Kerry S.
AU - Welch, Whitney
AU - Cottrell, Alison
AU - Lloyd, Gillian R.
AU - Gavin, Kara
AU - Cella, David
AU - Ackermann, Ronald T.
AU - Siddique, Juned
AU - Spring, Bonnie
N1 - Funding Information:
This work was supported by the National Institutes of Health [ K07CA196840 and U54CA193419 ] awarded to Siobhan Phillips.
Publisher Copyright:
© 2018 Elsevier Inc.
PY - 2018/3
Y1 - 2018/3
N2 - Fit2Thrive is a theory-guided physical activity promotion trial using the Multiphase Optimization Strategy (MOST) to test efficacy for improving physical activity of five technology-supported physical activity promotion intervention components among breast cancer survivors. This trial will recruit 256 inactive breast cancer survivors nationwide. All participants will receive the core intervention which includes a Fitbit and standard self-monitoring Fit2Thrive smartphone application which will be downloaded to their personal phone. Women will be randomized to one of 32 conditions in a factorial design involving five factors with two levels: support calls (No vs. Yes), app type (standard vs. deluxe), text messaging (No vs. Yes), online gym (No vs. Yes) and Fitbit Buddy (No vs. Yes). The proposed trial examines the effects of the components on physical activity at 12 and 24 weeks. Results will support the selection of a final package of intervention components that has been optimized to maximize physical activity and is subject to an upper limit of cost. The optimized intervention will be tested in a future trial. Fit2Thrive is the first trial to use the MOST framework to develop and test a physical activity promotion intervention in breast cancer survivors and will lead to an improved understanding of how to effectively change survivors' physical activity. These findings could result in more scalable, effective physical activity interventions for breast cancer survivors, and, ultimately, improve health and disease outcomes.
AB - Fit2Thrive is a theory-guided physical activity promotion trial using the Multiphase Optimization Strategy (MOST) to test efficacy for improving physical activity of five technology-supported physical activity promotion intervention components among breast cancer survivors. This trial will recruit 256 inactive breast cancer survivors nationwide. All participants will receive the core intervention which includes a Fitbit and standard self-monitoring Fit2Thrive smartphone application which will be downloaded to their personal phone. Women will be randomized to one of 32 conditions in a factorial design involving five factors with two levels: support calls (No vs. Yes), app type (standard vs. deluxe), text messaging (No vs. Yes), online gym (No vs. Yes) and Fitbit Buddy (No vs. Yes). The proposed trial examines the effects of the components on physical activity at 12 and 24 weeks. Results will support the selection of a final package of intervention components that has been optimized to maximize physical activity and is subject to an upper limit of cost. The optimized intervention will be tested in a future trial. Fit2Thrive is the first trial to use the MOST framework to develop and test a physical activity promotion intervention in breast cancer survivors and will lead to an improved understanding of how to effectively change survivors' physical activity. These findings could result in more scalable, effective physical activity interventions for breast cancer survivors, and, ultimately, improve health and disease outcomes.
KW - Breast cancer survivors
KW - Multiphase Optimization Strategy
KW - Physical activity
KW - Technology
UR - http://www.scopus.com/inward/record.url?scp=85041586113&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85041586113&partnerID=8YFLogxK
U2 - 10.1016/j.cct.2018.01.001
DO - 10.1016/j.cct.2018.01.001
M3 - Article
C2 - 29330081
AN - SCOPUS:85041586113
SN - 1551-7144
VL - 66
SP - 9
EP - 19
JO - Contemporary Clinical Trials
JF - Contemporary Clinical Trials
ER -